|
Shiverer (Mbp null) |
Decreased axon caliber/neurofilament phosphorylation, minimal axon degeneration |
Rosenbluth, 1980; Brady et al., 1999
|
|
Plp1 null |
Progressive axon loss, axonal spheroids containing multivesicular bodies, disorganized cytoskeletal components, and membranous organelles, impaired axon transport, and microtubule abnormalities |
Klugmann et al., 1997; Griffiths et al., 1998; Garbern et al., 2002; Edgar et al., 2004; Yin et al., 2016
|
|
Cnp null |
Mislocalization of voltage-gated sodium channels and Caspr, progressive axon loss, axonal spheroids with accumulations of membranous organelles, impaired axon transport, and impaired formation and maintenance of cytoplasmic channels |
Lappe-Siefke et al., 2003; Rasband et al., 2005; Snaidero et al., 2017
|
|
Mag null |
Decreased axon caliber/neurofilament phosphorylation, progressive axon loss, increased susceptibility to EAE/neurotoxic injury, and decreased Cdk5/Erk1/2 kinase activity |
Fruttiger et al., 1995; Yin et al., 1998; Dashiell et al., 2002; Pan et al., 2005; Nguyen et al., 2009
|
| EAE |
Axon loss, irreversible cytoskeletal fragmentation, impaired mitochondrial morphology and trafficking, impaired axon transport, oxidative damage, and increased axoplasmic calcium |
Siffrin et al., 2010; Nikić et al., 2011; Sorbara et al., 2014; Höflich et al., 2016; Mei et al., 2016
|
| Lysolecithin |
Impaired axon transport, increased mitochondrial stationary site size and transport rate, and disrupted nodal architecture |
Arroyo et al., 2004; Kiryu-Seo et al., 2010; Ohno et al., 2014; Höflich et al., 2016; Schultz et al., 2017
|
| Cuprizone |
Axon loss, impaired axon transport, and increased mitochondrial stationary site size |
Ohno et al., 2014; Sachs et al., 2014; Höflich et al., 2016; Schultz et al., 2017
|
| DT ablation |
Axon loss, impaired axon transport, and neurofilament dephosphorylation |
Traka et al., 2010, 2016; Pohl et al., 2011; Oluich et al., 2012
|
